Search results for "Budget impact"

showing 4 items of 4 documents

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination s…

2014

Streptococcus pneumoniae is a major cause of human infectious diseases worldwide. Despite this documented evidence, data on pneumococcal disease rates among general populations are scant because of the frequent lack of cultural identification. In this study we propose a model for estimating the burden of pneumococcal pneumonia on hospitalizations. The study was performed by analyzing administrative and clinical data of patients aged 50 years or older, resident in Sicily, and hospitalized, from 2005 to 2012. Demographic information, admission/discharge dates, discharge status, and up to 6 discharge diagnoses coded according to ICD-9 CM were collected for each hospitalized patient. During the…

MalePediatricsmedicine.medical_specialtyImmunologyPopulationSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePneumococcal VaccinesCost of IllnessHealth careStreptococcus pneumoniaemedicineHumansImmunology and AllergyeducationSicilyAgedAged 80 and overPharmacologyeducation.field_of_studySicily Streptococcus pneumoniae hospitalizations model estimating pneumococcal pneumoniabusiness.industryVaccinationBudget impactMiddle AgedPneumonia Pneumococcalmedicine.diseaseHospitalizationVaccinationPneumoniaPopulation SurveillancePneumococcal pneumoniaFemaleDiagnosis codebusinessResearch PaperHuman Vaccines & Immunotherapeutics
researchProduct

Developing and testing a discrete event simulation model to evaluate budget impacts of diabetes prevention programs

2020

Type 2 diabetes (T2D) is one of the most rapidly increasing non-communicable diseases worldwide. Lifestyle interventions are effective in preventing T2D but also resource intensive. This study evaluated with discrete event simulation (DES) the relative budget impacts of three hypothetical diabetes prevention programs (DPP), including group-based contact intervention, digital program with human coaching and fully automated program. The data for simulation were derived from research literature and national health and population statistics. The model was constructed using the iGrafx Process for Six Sigma software and simulations were carried out for 10 years. All simulated interventions produc…

mallintaminenProcess (engineering)Computer scienceCost-Benefit AnalysisPsychological interventiondiabetes preventionHealth InformaticsCoaching03 medical and health sciences0302 clinical medicineResource (project management)Cost SavingsIntervention (counseling)Humansbudget impact analysissimulointiComputer Simulation030212 general & internal medicineDiscrete event simulationLife Style030304 developmental biologydiscrete event simulation0303 health sciencesdiabetesbusiness.industryBehavior changeSix SigmaComputer Science Applicationshealth behavior changeDiabetes Mellitus Type 2Risk analysis (engineering)terveyskäyttäytymineninterventiohoitoennaltaehkäisybusinessaikuistyypin diabetesJournal of Biomedical Informatics
researchProduct

2SPD-025 Application of hazard vulnerability analysis to evaluate the risk level of medicine shortages

2020

Background and importance Drug shortages have become a worldwide phenomenon which has repercussions on patient care and on the hospital’s budget. Aim and objectives The aim of our study was to assess the risk of shortages of drugs included in our hospital therapeutic formulary (HTF), for which there is shortage reporting, using a hazard vulnerability analysis (HVA). Material and methods We performed an HVA on 43 drugs in our HTF, which were also included in the Italian Medicines Agency list of shortages. The HVA used to assign the risk of shortage (ROS) included three macro areas: probability that the shortages will occur based on shortages in the past 2 years; magnitude factors which incre…

Risk levelbusiness.industryVulnerability assessmentEnvironmental healthPsychological interventionMedicineEconomic shortageBudget impactFormularyMedium RiskbusinessPatient careSection 2: Selection, Procurement and Distribution
researchProduct

Impact of orphan drugs on Latvian budget

2016

Background Number of orphan medicinal products on the market and number of rare disease patients, taking these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor, along with the cost-effectiveness of orphan drugs, is often considered in the reimbursement decisions, directly affecting accessibility of rare disease therapies. The current study aims to assess the budget impact of orphan drugs in Latvia. Methods Our study covered a 5-year period, from 2010 to 2014. Impact of orphan drugs on Latvian budget was estimated from the National Health Service’s perspective. It was calculated in absolute values and relative to total pharmaceuti…

Budgetsendocrine systemOrphan Drug ProductionCost-Benefit AnalysisPharmacology toxicologyPharmacologyOrphan drug03 medical and health sciences0302 clinical medicineOrphan Drug ProductionOrphan drugsHumansEnzyme Replacement TherapyGenetics(clinical)Pharmacology (medical)030212 general & internal medicinehealth care economics and organizationsGenetics (clinical)ReimbursementMucopolysaccharidosis IIMedicine(all)Public economicsCost–benefit analysisResearch030503 health policy & servicesExpenditureLatvianGeneral MedicineBudget impactLatviaReimbursementlanguage.human_languageBudget impactlanguageBusiness0305 other medical scienceRare diseaseOrphanet Journal of Rare Diseases
researchProduct